This story originally ran on Dec. 10.
By Tony Fong
When Vermillion filed its 510(k) application with the US Food and Drug Administration for its ovarian cancer diagnostic in June 2008, the company was facing two daunting obstacles.
GenomeWeb Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.
A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.
The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."
In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.
This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.